AU2016347863B2 - Plasminogen replacement therapy for plasminogen-deficiency - Google Patents

Plasminogen replacement therapy for plasminogen-deficiency Download PDF

Info

Publication number
AU2016347863B2
AU2016347863B2 AU2016347863A AU2016347863A AU2016347863B2 AU 2016347863 B2 AU2016347863 B2 AU 2016347863B2 AU 2016347863 A AU2016347863 A AU 2016347863A AU 2016347863 A AU2016347863 A AU 2016347863A AU 2016347863 B2 AU2016347863 B2 AU 2016347863B2
Authority
AU
Australia
Prior art keywords
plasminogen
day
subject
activity
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016347863A
Other languages
English (en)
Other versions
AU2016347863A1 (en
Inventor
Pierre Laurin
Stacy PLUM
Martin Robitaille
Karen Thibaudeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biotherapeutics Inc
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of AU2016347863A1 publication Critical patent/AU2016347863A1/en
Application granted granted Critical
Publication of AU2016347863B2 publication Critical patent/AU2016347863B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016347863A 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency Active AU2016347863B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
US62/250,235 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (2)

Publication Number Publication Date
AU2016347863A1 AU2016347863A1 (en) 2018-06-07
AU2016347863B2 true AU2016347863B2 (en) 2023-11-09

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016347863A Active AU2016347863B2 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Country Status (16)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
FI (1) FI3370760T3 (enExample)
IL (1) IL258913B (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
RU (1) RU2736831C2 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
EP3391902B1 (en) * 2015-12-18 2023-10-18 Talengen International Limited Plasminogen for use in the treatment of diabetic angiocardiopathy
CN109069567A (zh) 2015-12-18 2018-12-21 泰伦基国际有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
CN115845037A (zh) * 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
WO2017161354A1 (en) * 2016-03-17 2017-09-21 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
US11389515B2 (en) * 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TW201822809A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療高脂血症的方法
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3556380A4 (en) * 2016-12-15 2020-05-13 Talengen International Limited METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN
TWI763680B (zh) 2016-12-15 2022-05-11 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備藥物中的用途
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
ES3036897T3 (en) 2017-06-19 2025-09-25 Talengen Int Ltd Plasminogen for use in treating parkinson's and alzheimer's disease
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CA3127375A1 (en) * 2019-01-24 2020-07-30 Previpharma Consulting Gmbh Plasminogen for treating and preventing microthrombosis
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
WO2021214320A1 (en) 2020-04-23 2021-10-28 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020297A2 (en) * 2001-09-06 2003-03-13 Omnio Ab Method of improving wound healing
WO2008027000A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
WO1994018315A1 (en) * 1993-02-05 1994-08-18 Vascular Laboratories, Inc. Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
CN101573134B (zh) * 2006-08-28 2013-03-06 李季男 抗感染候选药物
NZ597452A (en) * 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
JP6343147B2 (ja) * 2010-08-30 2018-06-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 狭窄病変および血栓溶解療法のための剪断による制御放出
HUE068351T2 (hu) 2014-12-19 2024-12-28 Kedrion Biopharma Inc Plazminogént tartalmazó gyógyszerkészítmény és annak felhasználásai
WO2017101870A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020297A2 (en) * 2001-09-06 2003-03-13 Omnio Ab Method of improving wound healing
WO2008027000A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRAFT ET AL.: GRAEFES ARCH CLIN EXP OPHTHALMOL., vol. 238, no. 9, 1 September 2000 (2000-09-01), pages 797 - 800, *
SCHOTT ET AL.: N ENGL J MED., vol. 339, no. 23, 3 December 1998 (1998-12-03), pages 1679 - 1686, XP 055014574, ISSN: 0028-4793 *

Also Published As

Publication number Publication date
CA3002915C (en) 2024-01-16
CN108289935A (zh) 2018-07-17
FI3370760T3 (fi) 2025-12-05
US11291711B2 (en) 2022-04-05
KR102821400B1 (ko) 2025-06-18
RU2018120182A (ru) 2019-12-04
IL258913A (en) 2018-06-28
ZA201802820B (en) 2019-07-31
RU2018120182A3 (enExample) 2020-04-27
BR112018008965A2 (pt) 2018-11-21
JP6878423B2 (ja) 2021-05-26
TW201722463A (zh) 2017-07-01
RU2736831C2 (ru) 2020-11-20
EP3370760A1 (en) 2018-09-12
MY199581A (en) 2023-11-07
IL258913B (en) 2021-12-01
TWI801331B (zh) 2023-05-11
JP2018533589A (ja) 2018-11-15
WO2017077380A1 (en) 2017-05-11
MX2018005588A (es) 2018-11-09
AU2016347863A1 (en) 2018-06-07
NZ742657A (en) 2024-04-26
US20190231854A1 (en) 2019-08-01
CA3002915A1 (en) 2017-05-11
KR20180083348A (ko) 2018-07-20
BR112018008965A8 (pt) 2019-02-26
EP3370760B1 (en) 2025-10-01
EP3370760A4 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
AU2016347863B2 (en) Plasminogen replacement therapy for plasminogen-deficiency
Fourrier et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies
Stefoni et al. Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients
Allaart et al. Hereditary protein S deficiency in young adults with arterial occlusive disease
Shapiro et al. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency
Gando et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients
Ishihara et al. Effect of plasma fibrinogen, high-sensitive C-reactive protein, and cigarette smoking on carotid atherosclerosis: the Suita study
EA002496B1 (ru) Способы лечения состояний гиперкоагуляции или приобретенной недостаточности белка с
JP2020524689A (ja) Ｐａｉ−１過剰発現に関連する状態のプラスミノーゲン処置
Zöller et al. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease
Roldán et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis
US20090018082A1 (en) Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma
JP6000259B2 (ja) 止血障害治療用第ｉｉ因子およびフィブリノーゲン
Roldán et al. Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction
EP3424550A1 (en) Gas mixtures containing low concentrations of xenon and argon provide neuroprotection without inhibiting the catalytic activity of thrombolytic agents
Peus et al. Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression
JP2009520696A (ja) 出血性ショックおよびその続発症を治療するための製剤
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
Pomero et al. Direct oral anticoagulants in factor VII deficiency patient
Lin et al. Atypical pulmonary thromboembolism caused by the mutation site SERPINC1 of the antithrombin III gene: A case report
Ranieri et al. Defibrotide in the treatment of Raynaud's phenomenon in patients with progressive systemic sclerosis or essential mixed cryoglobulinemia
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
Kageyama et al. Prevention of neointima formation after balloon injury by anti-human vWF monoclonal antibody, AJvW-2 in guinea pigs
ADVERSE A STUDY ON SERUM FIBRINOGEN AS AN INDEPENDENT PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN KNOWN DIABETIC CORONARY ARTERY DISEASE PATIENTS

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)